Saturday, January 07, 2017 9:01:58 AM
http://www.onemednews.com/2016/12/31/neurotrope-alzheimers/
Neurotrope BioScience, (OTCQB:NTRP), formed in 2012, is at the forefront of the biotech industry and is focused on developing new therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders.
The company’s experience, capabilities, and passion for innovative and novel drug therapies have enabled it to build a development pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat diseases such as Alzheimer’s dementia and the Orphan diseases, Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC).
Neurotrope’s molecular mechanisms of memory that were responsible for classical conditioning of the Mollusk Hermissenda. They then demonstrated that these molecular mechanisms were conserved across evolution, providing a basis for memory-specific changes for synaptic function in a variety of animal species and associative learning paradigms.
Subsequently, they have discovered a convergence of memory-specific molecular and synaptic functions with the pathophysiology of Alzheimer’s disease, particularly involving biochemical cascades in which the isozymes of PKC play a central role. PKC activators, for example, phosphorylate the mRNA stabilizing proteins (HuD, HuR) during associative learning.
The mRNA stabilizing proteins then move into the dendritic tree to stabilize and regulate an ensemble of synaptic remodeling proteins such as GAP43, BDNF, IGF, and NGF. Similarly, memory-specific activation of PKC isozymes activate additional pathways to control learning specific protein synthesis via the NFkB and CREB pathways.
These same pathways are targeted by toxic Beta elevated in Alzheimer’s tissues to cause the synaptic loss characteristically demonstrated at autopsy and that correlates with the dementia shown by patients clinically. Thus, the convergence of molecular pathways of memory and the pathologic pathways responsible for neuro-degeneration has provided a whole new strategy for treatment in our aging population.
Bryostatin, currently undergoing a 148 patient phase 2 trial, has shown remarkable efficacy inducing new synaptic growth in fully differentiated nervous systems, for rescuing dying neurons, and for the normalization of A Beta and amyloid plaques. These new findings on associative memory mechanisms are guiding development of drug discovery with the potential to treat the loss of synapses and to prevent neuronal death in neuro-degenerative disorders such as, Alzheimer’s disease, stroke, traumatic brain injury, fragile x, Neimann Pick type C, Rett Syndrome and attention-deficit disorders.
Recent VTVT News
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT • PR Newswire (US) • 03/19/2024 12:30:00 PM
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:47:37 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/06/2024 12:52:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:04:31 PM
- vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:26:55 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:14:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:08:30 PM
- vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE • PR Newswire (US) • 02/22/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:26:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:28:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:21:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:23:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:22:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:19:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:31 PM
- vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:16 PM
- vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 01:00:00 PM
- vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 11/02/2023 12:00:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM